Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PURVI KOTHARI MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1336280031
CMS profile
15061
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,287.71

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,661.01 8
Food and Beverage $576.70 23
Honoraria $50.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,614.18 12
Eli Lilly and Company $464.42 17
Novo Nordisk AS $136.66 1
Flexion Therapeutics, Inc. $50.00 1
GlaxoSmithKline, LLC. $22.45 1

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PURVI KOTHARI MEHRA

NPI 1336280031 · CMS profile ID 15061

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $2,287.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $22.4507/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670915843 CMS
Eli Lilly and Company $8.3506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709012135 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709013675 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014159 CMS
Eli Lilly and Company $3.3406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014515 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014857 CMS
Eli Lilly and Company $25.9906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015171 CMS
Eli Lilly and Company $44.5506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015173 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015175 CMS
Eli Lilly and Company $33.4106/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015337 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015339 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016879 CMS
Eli Lilly and Company $4.4606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016881 CMS
Eli Lilly and Company $11.1406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016883 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016885 CMS
Eli Lilly and Company $2.6006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017571 CMS
Eli Lilly and Company $6.5006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017573 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017575 CMS
Novo Nordisk AS $136.6606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544125 CMS
Merck Sharp & Dohme Corporation $13.9105/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804301 CMS
Merck Sharp & Dohme Corporation $30.8205/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804747 CMS
Merck Sharp & Dohme Corporation $78.4105/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805031 CMS
Merck Sharp & Dohme Corporation $103.1305/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804299 CMS
Merck Sharp & Dohme Corporation $24.9905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804585 CMS
Merck Sharp & Dohme Corporation $247.0605/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804745 CMS
Merck Sharp & Dohme Corporation $50.0005/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804749 CMS
Merck Sharp & Dohme Corporation $81.1905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805033 CMS
Merck Sharp & Dohme Corporation $209.0005/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804583 CMS
Merck Sharp & Dohme Corporation $247.0605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804743 CMS
Merck Sharp & Dohme Corporation $502.3905/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804751 CMS
Merck Sharp & Dohme Corporation $26.2205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806407 CMS
Flexion Therapeutics, Inc. $50.0001/08/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705866853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,287.71 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Recipient $375.00 2
PY2022 Principal investigator $30,891.10 5
PY2021 Principal investigator $3,333,813.44 59
PY2020 Recipient $3,034.66 5
PY2020 Principal investigator $1,118,926.99 96
PY2019 Recipient $6,389.04 5
PY2019 Principal investigator $1,783,635.66 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

139 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $1,978.59 12/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447033
Principal investigator 1 Novo Nordisk AS $1,797.00 12/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,043.97 12/18/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741461
Principal investigator 1 Novo Nordisk AS $3,601.69 12/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,643.08 12/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741459
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,139.10 12/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685012477
Principal investigator 1 Merck Sharp & Dohme Corporation $8,473.00 12/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691490645
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 12/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691504027
Principal investigator 1 Novo Nordisk AS $30.00 12/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668185
Principal investigator 1 Novo Nordisk AS $23.06 12/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668187
Principal investigator 1 Novo Nordisk AS $9.99 12/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668189
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,661.20 11/28/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,053.06 11/28/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741457
Principal investigator 1 Merck Sharp & Dohme Corporation $11,700.00 11/26/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691446985
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,275.00 11/22/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629169107
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $500.00 11/22/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629169365
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,350.00 11/22/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629169621
Principal investigator 1 Novo Nordisk AS $22.50 11/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668183
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,038.01 11/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741453
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 11/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685012435
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 11/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685012441
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,233.10 11/06/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685012451
Principal investigator 1 Novo Nordisk AS $4,346.73 10/29/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447021
Principal investigator 1 Novo Nordisk AS $9.99 10/24/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668179
Principal investigator 1 Novo Nordisk AS $23.06 10/24/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668181
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,714.25 10/23/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,711.12 10/23/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741451
Principal investigator 1 Merck Sharp & Dohme Corporation $2,793.72 10/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691336149
Principal investigator 1 Merck Sharp & Dohme Corporation $5,593.43 10/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691337871
Principal investigator 1 Merck Sharp & Dohme Corporation $962.85 10/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691372391
Principal investigator 1 Merck Sharp & Dohme Corporation $25,260.00 10/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691372823
Principal investigator 1 Novo Nordisk AS $5.30 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668167
Principal investigator 1 Novo Nordisk AS $18.00 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668169
Principal investigator 1 Novo Nordisk AS $60.00 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668171
Principal investigator 1 Novo Nordisk AS $6.50 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668173
Principal investigator 1 Novo Nordisk AS $9.80 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668175
Principal investigator 1 Novo Nordisk AS $144.00 10/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 10/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639741445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,538.51 10/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741447
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,996.00 10/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685012445
Principal investigator 1 PFIZER INC. $242,196.87 10/04/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND ACTIVECONTROLLED MULTICENTER STUDY OF THE LONGTERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 671658835
Principal investigator 1 Novo Nordisk AS $23.06 09/27/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668217
Principal investigator 1 Novo Nordisk AS $9.99 09/27/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668219
Principal investigator 1 Merck Sharp & Dohme Corporation $43,042.50 09/26/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346827
Principal investigator 1 Novo Nordisk AS $2,364.76 09/26/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47,520.54 09/25/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741443
Principal investigator 1 Eli Lilly and Company $110,749.00 09/23/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654287505
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 09/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346221
Principal investigator 1 Merck Sharp & Dohme Corporation $3,870.00 09/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,856.57 09/11/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741441
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 09/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691518351
Principal investigator 1 Merck Sharp & Dohme Corporation $176.10 09/06/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691355845
Principal investigator 1 Novo Nordisk AS $500.00 09/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447023
Principal investigator 1 Novo Nordisk AS $3,000.00 09/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447025
Principal investigator 1 Novo Nordisk AS $1,000.00 09/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 692447027
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 09/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691515431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,916.78 08/28/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741437
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,250.61 08/28/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741439
Principal investigator 1 Merck Sharp & Dohme Corporation $53,537.50 08/20/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,342.91 08/14/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741435
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691355779
Principal investigator 1 Novo Nordisk AS $4.80 08/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668211
Principal investigator 1 Novo Nordisk AS $4.80 08/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668213
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 08/07/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691502007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.00 08/07/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741433
Principal investigator 1 Merck Sharp & Dohme Corporation $36,785.00 08/06/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346823
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 07/31/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691508557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $41,711.46 07/31/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,280.00 07/23/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639741395
Principal investigator 1 Eli Lilly and Company $8,670.67 07/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 654289099
Principal investigator 1 Merck Sharp & Dohme Corporation $186.00 07/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691508551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,494.69 07/18/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639741393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,992.47 07/17/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,957.59 07/02/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741427
Principal investigator 1 AbbVie, Inc. $11,785.00 06/27/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
M18-891 No dispute reported 06/30/2026 647621741
Principal investigator 1 Novo Nordisk AS $9.98 06/27/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668209
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $21,578.40 06/26/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741425
Principal investigator 1 Novo Nordisk AS $144.09 06/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668215
Principal investigator 1 Merck Sharp & Dohme Corporation $1,931.70 06/17/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691419713
Principal investigator 1 Merck Sharp & Dohme Corporation $472.80 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691369118
Principal investigator 1 Novo Nordisk AS $36.00 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668191
Principal investigator 1 Novo Nordisk AS $9.80 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668193
Principal investigator 1 Novo Nordisk AS $6.50 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668195
Principal investigator 1 Novo Nordisk AS $60.00 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668197
Principal investigator 1 Novo Nordisk AS $9.00 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668199
Principal investigator 1 Novo Nordisk AS $49.98 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668201
Principal investigator 1 Novo Nordisk AS $5.30 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668203
Principal investigator 1 Novo Nordisk AS $11.38 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668205
Principal investigator 1 Novo Nordisk AS $1.14 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668207
Principal investigator 1 Novo Nordisk AS $75.00 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668221
Principal investigator 1 Novo Nordisk AS $117.78 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $33,240.66 06/12/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741423
Principal investigator 1 Merck Sharp & Dohme Corporation $3,863.40 06/10/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691410269
Principal investigator 1 Novo Nordisk AS $63.52 06/10/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 706668165
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,764.00 06/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741419
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,150.00 06/05/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741421
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,588.62 05/29/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741391
Recipient Teva Pharmaceuticals USA, Inc. $15.00 05/28/2019 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027707
Recipient Teva Pharmaceuticals USA, Inc. $15.89 05/28/2019 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027715
Recipient Teva Pharmaceuticals USA, Inc. $29.15 05/28/2019 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027721
Recipient Teva Pharmaceuticals USA, Inc. $96.00 05/28/2019 Covered Recipient Physician A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027729
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15.00 05/24/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027529
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $15.08 05/24/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027537
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $43.77 05/24/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027545
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $45.03 05/24/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027551
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $213.57 05/24/2019 Non-covered Recipient Individual A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 685027561
Principal investigator 1 Merck Sharp & Dohme Corporation $2,008.80 05/19/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691480397
Principal investigator 1 Merck Sharp & Dohme Corporation $884.28 05/17/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691334259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40,598.62 05/15/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741389
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,877.32 05/14/2019 Non-covered Recipient Entity
Artemis Clinical Research
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis No dispute reported 06/30/2026 639763419
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/14/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691346831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $258.30 05/09/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC LOW BACK PAIN AND OSTEOARTHRITIS OF THE HIP OR KNEE No dispute reported 06/30/2026 639741387
Principal investigator 1 PFIZER INC. $82,152.85 05/07/2019 Non-covered Recipient Entity
Artemis Institute for Clinical Research LLC
A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN No dispute reported 06/30/2026 671655371
Principal investigator 1 Flexion Therapeutics, Inc. $8,500.00 05/01/2019 Non-covered Recipient Entity
Artemis Institute for Clinical Research
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 705979749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35,959.86 05/01/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741385
Principal investigator 1 Merck Sharp & Dohme Corporation $167.30 04/26/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain No dispute reported 06/30/2026 691480393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35,594.16 04/24/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741417
Principal investigator 1 Merck Sharp & Dohme Corporation $7,500.00 04/23/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-AGE No dispute reported 06/30/2026 691312429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,221.33 04/10/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741415
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50,077.53 03/27/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741413
Principal investigator 1 Merck Sharp & Dohme Corporation $2,361.25 03/21/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain No dispute reported 06/30/2026 691312275
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,999.92 03/19/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research - San Diego
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to No dispute reported 06/30/2026 639763417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,954.98 03/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741411
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54,672.35 03/04/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741409
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,796.00 02/20/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741407
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,624.00 02/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741403
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,495.54 02/13/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741405
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,660.00 02/07/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629168583
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,660.00 02/07/2019 Non-covered Recipient Entity
Artemis Institute For Clinical Research
Bay1002670 Fibroids Efficacy US / EU No dispute reported 06/30/2026 629168845
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $45,773.94 02/06/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741401
Principal investigator 1 Eli Lilly and Company $155,744.00 01/29/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654288057
Principal investigator 1 Merck Sharp & Dohme Corporation $83,008.00 01/24/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691306131
Principal investigator 1 Merck Sharp & Dohme Corporation $3,010.60 01/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain No dispute reported 06/30/2026 691306121
Principal investigator 1 Merck Sharp & Dohme Corporation $55.70 01/22/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2a, Proof of Concept, Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate the Efficacy and Safety of MK-7264 in Women with Moderate to Severe Endometriosis-related Pain No dispute reported 06/30/2026 691480399
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,957.80 01/16/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741399
Recipient Eli Lilly and Company $6,233.00 01/08/2019 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654283525
Principal investigator 1 Merck Sharp & Dohme Corporation $55,934.50 01/08/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691306127
Principal investigator 1 Eli Lilly and Company $17,009.05 01/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 654288185
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $214.50 01/03/2019 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639741397